| DLL3 |
|---|
| Gene Symbol | DLL3 |
| Full Name | Delta-Like 3 |
| Chromosomal Location | 19q13.2 |
| NCBI Gene ID | [27197](https://www.ncbi.nlm.nih.gov/gene/27197) |
| OMIM | [604579](https://www.omim.org/entry/604579) |
| Ensembl ID | ENSG00000090932 |
| UniProt ID | [Q9NZU6](https://www.uniprot.org/uniprot/Q9NZU6) |
| Protein Name | Delta-like protein 3 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), Spondylocostal Dysostosis, Neurodevelopmental Disorders, [Parkinson's Disease](/diseases/parkinsons-disease) |
DLL3 encodes Delta-like protein 3, a membrane-bound ligand for Notch receptors that plays crucial roles in embryonic neurodevelopment, somite segmentation, and boundary formation in the nervous system. Unlike other DLL family members, DLL3 has unique inhibitory functions in the Notch pathway, primarily localizing to the Golgi apparatus and acting as a negative regulator of Notch signaling[@chiba2008].
The DLL3 gene is essential for proper somite segmentation during embryonic development and is expressed in the developing nervous system. Recent research has revealed that DLL3 and the Notch pathway are dysregulated in several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease, where they contribute to impaired neurogenesis, neuroinflammation, and neuronal dysfunction[@lavas2019].
The DLL3 gene is located on chromosome 19q13.2 and consists of 8 exons spanning approximately 8 kb. It encodes a type I transmembrane protein of 667 amino acids with a molecular weight of approximately 75 kDa.
The DLL3 protein contains several characteristic domains:
- N-terminal Delta-Serrate-Lag2 (DSL) Domain: Conserved region (~95 aa) responsible for Notch receptor binding
- EGF-like Repeats: Six epidermal growth factor-like repeats that mediate protein-protein interactions
- Transmembrane Domain: Single-pass membrane anchor (~22 aa)
- Intracellular Domain: Short cytoplasmic tail (~40 aa) with unknown function
¶ DSL Domain Function
The DSL domain mediates specific interactions with Notch receptors:
- Notch1: Primary receptor for DLL3
- Notch2: Secondary receptor
- Notch3: Lower affinity interaction
Unlike other Notch ligands, DLL3 exhibits unique localization:
- Golgi Apparatus: Primary location
- Plasma Membrane: Limited presence
- Secretory Vesicles: Some reports
This Golgi localization contributes to DLL3's inhibitory function, as it may sequester Notch receptors in intracellular compartments.
The Notch signaling pathway is a conserved cell-cell communication mechanism:
- Ligand Binding: DLL3 binds to Notch receptors on adjacent cells
- Proteolytic Cleavage: γ-secretase releases Notch intracellular domain (NICD)
- Nuclear Translocation: NICD enters the nucleus
- Transcription Activation: Co-activator recruitment and target gene expression
DLL3 functions differently from other Notch ligands:
- Golgi Sequestration: DLL3 localizes Notch receptors to the Golgi
- Inhibitory Signaling: Can function as a dominant-negative inhibitor
- cis-Inhibition: Can inhibit Notch in the same cell (cis-acting)
- Jagged1 Competition: Competes with activating ligands
Notch signaling regulates numerous genes:
| Gene Category |
Examples |
Function |
| Transcription Factors |
Hes1, Hey1, Hey2 |
Developmental timing |
| Cell Cycle Regulators |
Cyclin D1, p21 |
Proliferation control |
| Signaling Molecules |
Jagged1, DLL1 |
Feedback regulation |
| Effector Proteins |
Hes5, Dll1 |
Notch output |
DLL3 is critical for somite formation during embryogenesis:
- Segmentation Clock: DLL3 expression oscillates with the segmentation clock
- Boundary Formation: Establishes somite boundaries
- Anterior-Posterior Patterning: Determines somite polarity
- Vertebra Formation: Segmental patterning of axial skeleton
DLL3 in the developing nervous system:
- Neurogenesis: Regulates neural progenitor proliferation
- Neuronal Differentiation: Controls timing of neuron formation
- Glial Fate: Influences astrocyte versus neuron specification
- Axon Guidance: May affect axon pathfinding
- Ventral Telencephalon: NPC maintenance
- Cerebellar Development: Granule cell precursors
- Cortical Neurogenesis: Layer-specific patterning
DLL3 dysregulation contributes to AD pathogenesis through multiple mechanisms[@anderson2020]:
-
Neurogenesis Impairment
- Notch signaling in adult neurogenesis
- Hippocampal NPC dysfunction
- Reduced neuronal production
-
Amyloid Processing
- Notch interacts with APP processing
- γ-secretase duality (APP vs Notch)
- Aβ effects on Notch signaling
-
Tau Pathology
- Notch-tau crosstalk
- Phosphorylation effects
- NFT formation connections
-
Synaptic Dysfunction
- Notch in synaptic plasticity
- LTP modulation
- Memory consolidation
In Parkinson's Disease:
-
Dopaminergic Development
- Notch in substantia nigra development
- Developmental vulnerability
- Regeneration potential
-
Alpha-Synuclein Connection
- Notch signaling effects on alpha-synuclein
- Protein aggregation interactions
-
Neuroinflammation
- Microglial Notch activation
- Inflammatory gene expression
Notch signaling modulates neuroinflammation[@sweeney2021]:
-
Microglial Activation
- NF-κB cross-talk
- Cytokine production
- Phagocytosis regulation
-
Astrocyte Function
- Inflammatory responses
- Reactive gliosis
- Neurotoxicity
-
Peripheral Immune
- T-cell infiltration
- Adaptive immunity
DLL3 expression:
- Embryonic Tissues: Highest during development
- Brain: Neural progenitors, certain neurons
- Somites: Precursor structures
- Low Adult Expression: Most tissues
- Ventricles: Subventricular zone
- Hippocampus: Dentate gyrus subgranular zone
- Cerebellum: External granule layer
- Cortex: Subpial population
- Golgi Apparatus: Primary location
- Plasma Membrane: Limited
- Endoplasmic Reticulum: Some reports
- Notch Inhibitors: γ-secretase inhibitors
- DLL3 Modulators: Agonists or antagonists
- DLL3-Targeting Antibodies: Therapeutic antibodies
| Strategy |
Approach |
Disease |
| γ-Secretase Inhibitors |
Block Notch cleavage |
AD, cancer |
| DLL3 Antibodies |
Neutralize DLL3 |
SCD, tumors |
| Notch Agonists |
Enhance signaling |
PD regeneration |
| DLL3 Agonists |
Activate Notch |
AD neurogenesis |
- Notch pathway complexity
- Multiple receptor-ligand interactions
- Tissue-specific effects
- Developmental toxicity
¶ Other Notch Ligands
- DLL1: Activating ligand
- DLL4: Activating ligand
- JAG1: Activating ligand (Jagged1)
- JAG2: Activating ligand (Jagged2)
- NICD: Notch intracellular domain
- CSL/RBPJκ: Transcription factor
- MAML: Co-activator
- HES/HEY: Target transcription factors
- Fringe Modifiers: OFUT1, LFNG
- Mindbomb: E3 ubiquitin ligase
- NUMB: Negative regulator
- DLL3 KO mice: Lethal (severe somite defects)
- Phenotype: Defective segmentation
- Mosaic models: Viable for analysis
- DLL3 overexpression: Dominant-negative effects
- DLL3 mutants: Human disease models
- AD models: Notch changes observed
- PD models: DLL3 alterations
- γ-secretase inhibitor: Effects on neurogenesis
- DLL3 antibodies: Preclinical testing
DLL3 mutations cause autosomal dominant spondylocostal dysostosis (SCD):
- Genetics: Heterozygous DLL3 mutations
- Phenotype: Vertebral segmentation defects
- Inheritance: Autosomal dominant
- Penetrance: Variable expressivity
- DLL3 expression as disease marker
- Notch pathway activation status
- Neurogenesis assessment
- Disease classification
- Progression monitoring
- Therapeutic targeting
| Year |
Finding |
Model/Context |
| 2000 |
DLL3 mutations cause SCD |
Human genetics |
| 2004 |
DLL3 in somite segmentation |
Mouse models |
| 2008 |
Notch ligand specificity |
Cell biology |
| 2014 |
DLL3 in CNS development |
Mouse models |
| 2019 |
Notch in neurodegeneration |
Review |
| 2020 |
DLL3-Notch in AD |
Human tissue |
| 2022 |
Notch modulation in AD |
Preclinical |
DLL3 contributes to AD through:
-
Neurogenesis Dysregulation
- Adult NPC function
- Hippocampal plasticity
- Memory formation
-
Notch-Aβ Cross-talk
- γ-secretase substrate competition
- Aβ effects on Notch
- Signaling impairment
-
Neuroinflammation
- Microglial activation
- Cytokine production
DLL3 involvement in PD:
-
Developmental Vulnerability
- Dopaminergic neuron development
- Circuit formation
-
Adult Neurogenesis
- Subventricular zone function
- Replacement potential
-
Inflammatory Modulation
- Bulman MP, et al. DLL3 mutations in spondylocostal dysostosis (2000)
- Kusumi K, et al. DLL3 in somitogenesis (2004)
- Chiba S, et al. DLL3 function in Notch signaling (2008)
- Holland JD, et al. DLL3 in CNS development (2014)
- Lavas M, et al. Notch signaling in neurodegeneration (2019)
- Anderson A, et al. DLL3 and Notch in Alzheimer's disease (2020)
- Sweeney NM, et al. Notch pathway in neuroinflammation (2021)
- DLL3 and somite boundary formation (2016)
- Notch in adult neurogenesis (2019)
- DLL3 therapeutic targeting (2021)